| | | | | Proton pump inhibitors in cirrhosis:Tradition or evidence based practice? | | | Francesca Lodato;Francesco Azzaroli;Maria Di Girolamo;Valentina Feletti;Paolo Cecinato;Andrea Lisotti;Davide Festi;Enrico Roda;Giuseppe Mazzella | | | Proton Pump Inhibitors (PPI) are very effective in inhibiting acid secretion and are extensively used in many acid related diseases. They are also often used in patients with cirrhosis sometimes in the absence of a specific acid related disease, with the aim of preventing peptic complications in patients with variceal or hypertensive gastropathic bleeding receiving multidrug treatment. Contradicting reports support their use in cirrhosis and evidence of their efficacy in this condition is poor. Moreover there are convincing papers suggesting that acid secretion is reduced in patients with liver cirrhosis. With regard to Helicobacter pylori (H pylori) infection, its prevalence in patients with cirrhosis is largely variable among different studies, and it seems that H pylori eradication does not prevent gastro-duodenal ulcer formation and bleeding. With regard to the prevention and treatment of oesophageal complications after banding or sclerotherapy of oesophageal varices, there is little evidence for a protective role of PPI. Moreover, due to liver metabolism of PPI, the dose of most available PPIs should be reduced in cirrhotics. In conclusion, the use of this class of drugs seems more habit related than evidence- based eventually leading to an increase in health costs.
【作者单位】：Department of Internal Medicine and Gastroenterology Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy;Bologna 40138;Italy
【分类号】：R575.2
【DOI】：CNKI:SUN:ZXXY.0.2008-19-005
【正文快照】：
INTRODUCTION Proton Pump Inhibitors (PPI) are extensively used in different acid related diseases. Their efficacy in inhibiting acid secretion is well known[1-4], and the use of this class of drugs has increased worldwide. They act through inhibition of t… | | |
| | |  推荐 CAJ下载  PDF下载 | | | CAJViewer7.0阅读器支持所有CNKI文件格式，AdobeReader仅支持PDF格式 | | | | Proton pump inhibitors in cirrhosis:Tradition or evidence based practice? | | | Francesca Lodato;Francesco Azzaroli;Maria Di Girolamo;Valentina Feletti;Paolo Cecinato;Andrea Lisotti;Davide Festi;Enrico Roda;Giuseppe Mazzella;Department of Internal Medicine and Gastroenterology;Gastroenterology Unit;University of Bologna;Bologna 40138;Italy | | | Proton Pump Inhibitors (PPI) are very effective in inhibiting acid secretion and are extensively used in many acid related diseases. They are also often used in patients with cirrhosis sometimes in the absence of a specific acid related disease, with the aim of preventing peptic complications in patients with variceal or hypertensive gastropathic bleeding receiving multidrug treatment. Contradicting reports support their use in cirrhosis and evidence of their efficacy in this condition is poor. Moreover there are convincing papers suggesting that acid secretion is reduced in patients with liver cirrhosis. With regard to Helicobacter pylori (H pylori) infection, its prevalence in patients with cirrhosis is largely variable among different studies, and it seems that H pylori eradication does not prevent gastro-duodenal ulcer formation and bleeding. With regard to the prevention and treatment of oesophageal complications after banding or sclerotherapy of oesophageal varices, there is little evidence for a protective role of PPI. Moreover, due to liver metabolism of PPI, the dose of most available PPIs should be reduced in cirrhotics. In conclusion, the use of this class of drugs seems more habit related than evidence- based eventually leading to an increase in health costs.
【Keyword】：Proton pump inhibitors;Cirrhosis;Helicoba- cter pylori;Peptic ulcer;CYP P450 |
| | | | | | 1 | Eriksson S, ,Langstrom G, Rikner L, Carlsson R, Naesdal J; Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. [M];Eur J Gastroenterol Hepatol; 1995年 | | 2 | Sachs G, Shin JM, Briving C, Wallmark B, Hersey S; The pharmacology of the gastric acid pump: the H+, K+ ATPase. [M];Annu Rev Pharmacol Toxicol; 1995年 | | 3 | Lo WC, Lin HJ, Wang K, Lee FY, Perng CL, Lin HC, Lee SD; Gastric secretion in Chinese patients with cirrhosis [M];J Clin Gastroenterol; 1996年 | | 4 | Lenz HJ, Struck T, Greten H, Koss MA, Eysselein VE, Walsh JH, Isenberg JI; Increased sensitivity of gastric acid secretion to gastrin in cirrhotic patients with portacaval shunt [M];J Clin Invest; 1987年 | | 5 | Kaur S, Kaur U, Agnihotri N, Tandon CD, Majumdar S; Modulation of acid secretion in common bile duct ligation- related gastropathy in Wistar rats [M];J Gastroenterol Hepatol; 2001年 | | 6 | Agnihotri N, Kaur U, Dhawan V, Dilawari JB; Extrahepatic portal hypertensive gastropathy in Wistar rats: modulation of acid secretion in isolated parietal cells. [M];Dig Dis Sci; 1998年 | | 7 | Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM; Meta-analysis: proton pump inhibitors vs. H2- receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. [M];Aliment Pharmacol Ther; 2003年 | | 8 | Gaur SK, Vij JC, Sarin SK, Anand BS; Gastric secretion in cirrhosis and non-cirrhotic portal fibrosis [M];Digestion; 1988年 | | 9 | Konturek SJ, Gonciarz M, Gonciarz Z, Bielanski W, Mazur W, Mularczyk A, Konturek PC, Goetze JP, Rehfeld JF; Progastrin and its products from patients with chronic viral hepatitis and liver cirrhosis [M];Scand J Gastroenterol; 2003年 | | 10 | Siringo S, Vaira D, Menegatti M, Piscaglia F, Sofia S, Gaetani M, Miglioli M, Corinaldesi R, Bolondi L; High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer [M];Dig Dis Sci; 1997年 |
|
|
|